250 related articles for article (PubMed ID: 8670088)
1. The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis.
Soto C; Castaño EM
Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):701-7. PubMed ID: 8670088
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's beta-amyloid peptide is conformationally modified by apolipoprotein E in vitro.
Soto C; Golabek A; Wisniewski T; Castaño EM
Neuroreport; 1996 Feb; 7(3):721-5. PubMed ID: 8733730
[TBL] [Abstract][Full Text] [Related]
3. Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease.
Soto C; Frangione B
Neurosci Lett; 1995 Feb; 186(2-3):115-8. PubMed ID: 7777177
[TBL] [Abstract][Full Text] [Related]
4. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides.
Alvarez A; Bronfman F; Pérez CA; Vicente M; Garrido J; Inestrosa NC
Neurosci Lett; 1995 Dec; 201(1):49-52. PubMed ID: 8830310
[TBL] [Abstract][Full Text] [Related]
5. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra.
Barrow CJ; Yasuda A; Kenny PT; Zagorski MG
J Mol Biol; 1992 Jun; 225(4):1075-93. PubMed ID: 1613791
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease: soluble oligomeric Abeta(1-40) peptide in membrane mimic environment from solution NMR and circular dichroism studies.
Mandal PK; Pettegrew JW
Neurochem Res; 2004 Dec; 29(12):2267-72. PubMed ID: 15672549
[TBL] [Abstract][Full Text] [Related]
7. The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation.
Golabek AA; Soto C; Vogel T; Wisniewski T
J Biol Chem; 1996 May; 271(18):10602-6. PubMed ID: 8631862
[TBL] [Abstract][Full Text] [Related]
8. The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide.
El-Agnaf OM; Guthrie DJ; Walsh DM; Irvine GB
Eur J Biochem; 1998 Sep; 256(3):560-9. PubMed ID: 9780232
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils.
El-Agnaf OM; Bodles AM; Guthrie DJ; Harriott P; Irvine GB
Eur J Biochem; 1998 Nov; 258(1):157-63. PubMed ID: 9851705
[TBL] [Abstract][Full Text] [Related]
10. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4.
Wood SJ; Wetzel R; Martin JD; Hurle MR
Biochemistry; 1995 Jan; 34(3):724-30. PubMed ID: 7827029
[TBL] [Abstract][Full Text] [Related]
11. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation.
Soto C; Castaño EM; Frangione B; Inestrosa NC
J Biol Chem; 1995 Feb; 270(7):3063-7. PubMed ID: 7852387
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
Watson D; Castaño E; Kokjohn TA; Kuo YM; Lyubchenko Y; Pinsky D; Connolly ES; Esh C; Luehrs DC; Stine WB; Rowse LM; Emmerling MR; Roher AE
Neurol Res; 2005 Dec; 27(8):869-81. PubMed ID: 16354549
[TBL] [Abstract][Full Text] [Related]
13. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease.
Hilbich C; Kisters-Woike B; Reed J; Masters CL; Beyreuther K
J Mol Biol; 1991 Mar; 218(1):149-63. PubMed ID: 2002499
[TBL] [Abstract][Full Text] [Related]
14. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E.
Castano EM; Prelli F; Wisniewski T; Golabek A; Kumar RA; Soto C; Frangione B
Biochem J; 1995 Mar; 306 ( Pt 2)(Pt 2):599-604. PubMed ID: 7534068
[TBL] [Abstract][Full Text] [Related]
15. Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease?
Permanne B; Adessi C; Fraga S; Frossard MJ; Saborio GP; Soto C
J Neural Transm Suppl; 2002; (62):293-301. PubMed ID: 12456072
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
17. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain.
Crescenzi O; Tomaselli S; Guerrini R; Salvadori S; D'Ursi AM; Temussi PA; Picone D
Eur J Biochem; 2002 Nov; 269(22):5642-8. PubMed ID: 12423364
[TBL] [Abstract][Full Text] [Related]
18. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides.
Hilbich C; Kisters-Woike B; Reed J; Masters CL; Beyreuther K
J Mol Biol; 1992 Nov; 228(2):460-73. PubMed ID: 1453457
[TBL] [Abstract][Full Text] [Related]
19. Assemblages of prion fragments: novel model systems for understanding amyloid toxicity.
Satheeshkumar KS; Murali J; Jayakumar R
J Struct Biol; 2004 Nov; 148(2):176-93. PubMed ID: 15477098
[TBL] [Abstract][Full Text] [Related]
20. X-ray diffraction and far-UV CD studies of filaments formed by a leucine-rich repeat peptide: structural similarity to the amyloid fibrils of prions and Alzheimer's disease beta-protein.
Symmons MF; Buchanan SG; Clarke DT; Jones G; Gay NJ
FEBS Lett; 1997 Jul; 412(2):397-403. PubMed ID: 9256259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
